Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE2 | P0DPD6 | 2/20 | 1.00 |
| ▸ | ECE1 | P42892 | 2/20 | 1.00 |
| ▸ | MUS81 | Q96NY9 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 2/20 | 0.89 |
| ▸ | PGR | P06401 | 1/20 | 0.73 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.70 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.67 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 5/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | SYK | P43405 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16653949 | 1.00 | ECE2 (1.00) | ECE2ECE1MUS81ARPGR | |
| SCHEMBL4570235 | 1.00 | ECE2 (1.00) | ECE2ECE1MUS81ARPGR | |
| SCHEMBL29695489 | 1.00 | ECE2 (1.00) | ECE2ECE1MUS81ARPGR | |
| SCHEMBL29695645 | 1.00 | ECE2 (1.00) | ECE2ECE1MUS81ARPGR | |
| SCHEMBL30077227 | 1.00 | ECE2 (1.00) | ECE2ECE1MUS81ARPGR | |
| SCHEMBL16653952 | 1.00 | ECE2 (1.00) | ECE2ECE1MUS81ARPGR | |
| SCHEMBL14983767 | 0.94 | AR (1.00) | ECE2ECE1MUS81ARPGR | |
| SCHEMBL1175104 | 0.87 | AR (0.82) | ECE2ECE1MUS81ARPGR | |
| SCHEMBL1175103 | 0.87 | AR (0.82) | ECE2ECE1MUS81ARPGR | |
| SCHEMBL29874298 | 0.87 | AR (0.82) | ECE2ECE1MUS81ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230020401-A1 | METABOLIC REPROGRAMMING OF IMMUNE CELLS TO ENHANCE THE EFFICACY OF PROPHYLACTIC AND THERAPEUTIC VACCINES | Sanford Burnham Prebys Medical Discovery Institute | 2023-01-19 | — | — | US | claimed |
| EP-4054615-A1 | METABOLIC REPROGRAMMING OF IMMUNE CELLS TO ENHANCE THE EFFICACY OF PROPHYLACTIC AND THERAPEUTIC VACCINES | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-09-14 | — | — | EP | claimed |
| WO-2026106912-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4743080-A2 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026090127-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090245-A1 | USE OF RAS INHIBITORS FOR TREATING CANCER | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090116-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108528-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | REVOLUTION MEDICINES INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108473-A1 | BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | GENERATION BIO CO (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260098073-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF E. COLI HEMOLYSIN DURING URINARY TRACT INFECTION | WASHINGTON UNIVERSITY (US) | 2026-04-09 | — | — | US | disclosed |
| US-12590961-B2 | Quantum dot conjugated virus spike protein for cell-based bio-sensing systems and drug screening | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2026-03-31 | — | — | US | disclosed |
| US-11499155-B2 | Dynamin 2 inhibitor for the treatment of centronuclear myopathies | UNIVERSITE DE STRASBOURG (FR) | 2022-11-15 | — | — | US | disclosed |
| EP-4054615-A1 | METABOLIC REPROGRAMMING OF IMMUNE CELLS TO ENHANCE THE EFFICACY OF PROPHYLACTIC AND THERAPEUTIC VACCINES | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022138700-A1 | ATOPIC SKIN DISEASE AMELIORATING AGENT, EXTERNAL AGENT FOR SKIN, AND COSMETIC | ピアス株式会社 | 2022-06-30 | — | — | WO | disclosed |
| CN-108712913-B | Tri-part modulators of endosomal G protein-coupled receptors | 武田药品工业株式会社 | 2022-06-24 | — | — | CN | disclosed |
| US-20220175714-A1 | USE OF RIVASTIGMINE IN PREPARATION OF ANTI-RADIATION MEDICAMENT | SOOCHOW UNIVERSITY (CN) | 2022-06-09 | — | — | US | disclosed |
| US-11324832-B2 | Tripartite modulators of endosomal G protein-coupled receptors | ENDOSOME THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| CN-114146100-A | Application of bifidobacterium animalis subsp lactis BLA80 in preparation of drugs or foods for resisting diarrhea caused by rotavirus infection | 微康益生菌(苏州)股份有限公司 | 2022-03-08 | — | — | CN | disclosed |
| US-20220047719-A1 | ENHANCING SUBCUTANEOUS INJECTION AND TARGET TISSUE ACCUMULATION OF NANOPARTICLES VIA CO-ADMINISTRATION WITH MACROPINOCYTOSIS INHIBITORY NANOPARTICLES (MINP) | NORTHWESTERN UNIVERSITY | 2022-02-17 | — | — | US | disclosed |
| US-20220034884-A1 | Quantum Dot Conjugated Virus Spike Protein for Cell-Based Bio-Sensing Systems and Drug Screening | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11324832-B2 | Tripartite modulators of endosomal G protein-coupled receptors | NTSR1, NTSR2, MRGPRX2 | ECE2 2046/4885ECE1 1648/4885MUS81 4670/4885 |
| US-12590961-B2 | Quantum dot conjugated virus spike protein for cell-based bio-sensing systems and drug screening | ACE2, ACE, SARS1 | ECE2 111/4885ECE1 653/4885MUS81 3077/4885 |
| US-20260098073-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF E. COLI HEMOLYSIN DURING URINARY TRACT INFECTION | LDLR, CLTA, LRP6 | ECE2 607/4885ECE1 418/4885MUS81 1558/4885 |
| US-20260108473-A1 | BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | CD47, PLTP, CETP | ECE2 4833/4885ECE1 4845/4885MUS81 4722/4885 |
| US-20260108528-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | KRAS, NRAS, RAB1A | ECE2 3754/4885ECE1 3982/4885MUS81 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.